Suppr超能文献

墙草主要过敏原Par j 1的低变应原性变体:非特异性脂质转移蛋白植物家族的一员。

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family.

作者信息

Bonura A, Amoroso S, Locorotondo G, Di Felice G, Tinghino R, Geraci D, Colombo P

机构信息

Istituto di Biologia dello Sviluppo del Consiglio Nazionale delle Ricerche, Palermo, Italia.

出版信息

Int Arch Allergy Immunol. 2001 Sep;126(1):32-40. doi: 10.1159/000049492.

Abstract

BACKGROUND

Par j 1 represents a major allergenic component of Parietaria judaica (Pj) pollen, since it is able to induce an immunoglobulin E (IgE) response in 95% of Pj-allergic patients. It belongs to the non-specific lipid transfer protein family, sharing with them a common three-dimensional structure.

METHODS

Disulphide bond variants of the recombinant Par j 1 (rPar j 1) allergen were generated by site-directed mutagenesis, and the immunological activity of rPar j 1 and its conformational mutants was compared with the use of the skin prick test (SPT). The ability to bind IgE antibodies was evaluated by Western blot, ELISA and ELISA inhibition. T cell reactivity was measured by peripheral blood mononuclear cell proliferation assay.

RESULTS

The disruption of Cys14-Cys29 and Cys30-Cys75 bridging (PjA mutant) caused the loss of the majority of specific IgE-binding activity. Additional disruption of the Cys4-Cys52 bridge (PjC mutant) and the latter Cys50-Cys91 bridge (PjD mutant) led to the abolition of IgE-binding activity. On the SPT, PjB (lacking the Cys4-Cys52 and Cys50-Cys91 bridges) was still capable of triggering a type I hypersensitive reaction in 9 out of 10 patients, and PjA in 3 out of 10 patients, while PjC and PjD did not show any SPT reactivity. All the mutants preserved their T cell reactivity.

CONCLUSION

Recombinant hypoallergenic variants of the rPar j 1 allergen described herein may represent a useful tool for improved immunotherapy.

摘要

背景

Par j 1是墙草花粉的主要变应原成分,因为它能在95%的墙草花粉过敏患者中诱导免疫球蛋白E(IgE)反应。它属于非特异性脂质转移蛋白家族,与它们具有共同的三维结构。

方法

通过定点诱变产生重组Par j 1(rPar j 1)变应原的二硫键变体,并使用皮肤点刺试验(SPT)比较rPar j 1及其构象突变体的免疫活性。通过蛋白质印迹法、酶联免疫吸附测定(ELISA)和ELISA抑制来评估结合IgE抗体的能力。通过外周血单个核细胞增殖试验测量T细胞反应性。

结果

Cys14-Cys29和Cys30-Cys75桥接的破坏(PjA突变体)导致大部分特异性IgE结合活性丧失。Cys4-Cys52桥接(PjC突变体)和后一个Cys50-Cys91桥接(PjD突变体)的额外破坏导致IgE结合活性丧失。在SPT中,PjB(缺少Cys4-Cys52和Cys50-Cys91桥接)仍能在10名患者中的9名中引发I型超敏反应,PjA在10名患者中的3名中引发该反应,而PjC和PjD未显示任何SPT反应性。所有突变体均保留其T细胞反应性。

结论

本文所述的rPar j 1变应原的重组低变应原性变体可能是改进免疫疗法的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验